ETR
68
-3
VLO
42
2
PNR
74
5
PG
50
2
XEL
65
-2
DGX
48
-3
AA
38
-2
SLG
62
-4
WDC
38
-3
PWR
71
-3
FLS
76
-2
VZ
42
3
HES
66
3
WFC
80
-2
LEN
52
2
PAYX
57
-2
TXN
49
-6
IFF
53
2
COF
63
-4
DG
12
2
ETR
68
-3
VLO
42
2
PNR
74
5
PG
50
2
XEL
65
-2
DGX
48
-3
AA
38
-2
SLG
62
-4
WDC
38
-3
PWR
71
-3
FLS
76
-2
VZ
42
3
HES
66
3
WFC
80
-2
LEN
52
2
PAYX
57
-2
TXN
49
-6
IFF
53
2
COF
63
-4
DG
12
2
Financhill
Back

Marker Therapeutics 10K Form

Sell
33

MRKR
Marker Therapeutics

Last Price:
3.50
Seasonality Move:
8.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MRKR News And Ratings

See the #1 stock for the next 7 days that we like better than MRKR

MRKR Financial Statistics

Sales & Book Value

Annual Sales: $5.5M
Cash Flow: $-3.57M
Price / Cash Flow: 0
Annual Sales: $1.09
Price / Book: 3.42

Profitability

EPS (TTM): -1.18000
Net Income (TTM): $-10.37M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Marker Therapeutics Earnings Forecast

Key Marker Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for MRKR have been equal to 206.11% of Gross Profit Margin.
  • The Interest Expense is -0.03% of Operating Income.
  • Per Share Earnings over the last 17 years have been positive in 11 years.

Marker Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MRKR
CUSIP: 57055L
Website: http//www.markertherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MRKR Technical Analysis vs Fundamental Analysis

Sell
33
Marker Therapeutics (MRKR) is a Sell

Is Marker Therapeutics a Buy or a Sell?